VIVA and VEINS 2023: Late-Breaking Video Collection
Published: 27 November 2023
-
Views:
485
-
Likes:
7
-
Views:
485
-
Likes:
7
-
4m 2sPart 1 | Session 1 SAVER: Gender Subgroup Analysis Marianne Brodmann
-
7m 2sPart 1 | Session 2 VIVID: Venous Stent for the Iliofemoral Vein Mahmood K Razavi
-
5m 10sPart 1 | Session 3 DETOUR 1 and DETOUR2: PQ Bypass System for Percutaneous Femoropopliteal Bypass Sean Lyden
-
10m 22sPart 1 | Session 4 Wearable Non-Invasive Ultrasound for CLTI Mahmood K Razavi
-
10m 41sPart 1 | Session 5 STRIKE-PE: Indigo Aspiration System for PE Ido Weinberg
Overview
Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Part 1
Expert Interviews
About the episode
VIVA 23 - We are joined virtually by Dr Daniel Clair (Vanderbilt University Medical Center, US) in this short interview discussing the findings from the PROMISE II trial at 12 months.
The PROMISE II Trial aimed to investigate the safety and effectiveness of the LimFlow System in creating an arteriovenous connection in below the knee (BTK) vascular disease. The LimFlow System is intended to be used for minimally invasive endovascular procedures in patients with "no option" critical limb ischemia.
Interview Questions:
- What are the unmet needs for "no option" CLTI patients?
- What is the LimFlow system, and what are its unique features?
- What was the patient population and study design?
- What are your key findings at 12 months?
- What are your take-home messages?
- What further study is needed?
Recorded remotely from Tennessee, 2023.
Editor: Jordan Rance
Video Specialist: Oliver Miles
Comments